This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Forward Step By Step With Action Plan 2016 - Continued Revenue Growth - Significant Pipeline Progress

Stocks in this article: EVT

HAMBURG, Germany, March 26, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today reported financial results and corporate updates for the fiscal year ended 31 December 2012.

  • Growth trend continues

- Revenues +9% to € 87.3 m - Operating result adjusted € 1.4 m; net income € 2.5 m - Operating cash flow +18% to € 12.0 m - Strong and stable liquidity position of € 64.2 m - Expected revenues of € 90 m to € 100 m in 2013

  • Strong progress in all business units (EVT Execute /Integrate/Innovate) achieved

- Multiple new alliances and contract extensions (e.g. Bayer, CHDI and NIH) - Acceleration of EVT Innovate strategy through alliances with Harvard and Yale - Multiple milestones achieved with e.g. Andromeda/Teva, Boehringer Ingelheim, MedImmune, Novartis and Ono - Strategic alliance with 4-Antibody - Acquisition of CCS Cell Culture Service GmbH (after period-end)

  • Significant short- and mid-term pipeline catalysts

- DiaPep277 ®, positive Phase III results confirmed, data of second pivotal trial to come end of 2014 - Large Phase IIb trial started with EVT302 in Alzheimer`s Disease - Multiple clinical trials expected to start and read out in 2013/2014 (e.g. Phase II with EVT100 series in depression, several Phase I programmes in oncology, pain and other indications)

1. Operational performance – Good revenue growth, Milestones drive profitability

Revenue growth of 9%, operating result, R&D investments and liquidity in line with adjusted guidance

Evotec achieved continued profitable growth in 2012 with revenues up 9% to € 87.3 m (2011: € 80.1 m) and a net income of € 2.5 m (2011: € 6.7 m). The shift in revenues from milestones from Q4 2012 into 2013 had a negative effect on profitability, which as a result was lower than originally guided.

Growth in revenues was driven by the increase in revenues within the Company's drug discovery alliances and significant milestone payments through its collaborations in the amount of € 12.3 m (2011: € 10.5 m).

1 of 6

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs